• LIBTAYO® (cemiplimab-rwlc) Injection 350 mg by Regeneron Pharmaceuticals, Inc.

  
  

  REGENERON PHARM

  Libtayo Is Indicated For The Treatment Of Patients With Metastatic Cutaneous Squamous Cell Carcinoma (Cscc) Or Locally Advanced Cscc Who Are Not Candidates For Curative Surgery Or Curative Radiation.

  

• MONJUVI® (tafasitamab-cxix) sponsored by Incyte

  
  

  INCYTE CORPORAT

  Indications & Usage Diffuse Large B-Cell Lymphoma Monjuvi (Tafasitamab-Cxix), In Combination With Lenalidomide, Is Indicated For The Treatment Of Adult Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) Not Otherwise Specified, Including Dlbcl Arising From Low Grade Lymphoma, And Who Are Not Eligible For Autologous Stem Cell Transplant (Asct). This Indication Is Approved Under Accelerated Approval Based On Overall Response Rate. Continued Approval For This Ind

  

• Omvoh (mirikizumab-mrkz)

  
  

  LILLY

  Omvoh Mirikizumab-Mrkz 300 Mg/15 Ml Infusion, 100 Mg/Ml Injection] Is Indicated For The Treatment Of Adult Patients With Moderately To Severely Active Ulcerative Colitis.

  

• Stelo (blood-glucose sensor) by Dexcom

  
  

  DEXCOM, INC.

  Stelo (Blood-Glucose Sensor) By Dexcom

  

• fibryga® Fibrinogen (Human), sponsored by Octapharma USA, Inc.

  
  

  OCTAPHARMA USA

  Fibryga Is A Human Fibrinogen Concentrate Indicated For Fibrinogen Supplementation In Bleeding Patients With Acquired Fibrinogen Deficiency And In Treatment Of Acute Bleeding Episodes In Patients With Congenital Fibrinogen Deficiency, Including Afibrinogenemia And Hypofibrinogenemia. Fibryga Is Not Indicated For Dysfibrinogenemia.

  

• TRIPTODUR® (triptorelin) sponsored by Azurity Pharmaceuticals, Inc.

  
  

  ARBOR/AZURITY

  Triptodur Is Indicated For The Treatment Of Pediatric Patients 2 Years Of Age And Older With Central Precocious Puberty (Cpp).

  

• OPDIVO Qvantig™ (nivolumab + hyaluronidase-nvhy) sponsored by Bristol-Myers Squibb

  
  

  BMS PRIMARYCARE

  Opdivo Qvantig Is A Combination Of Nivolumab, A Programmed Death Receptor-1 (Pd-1)-Blocking Antibody, And Hyaluronidase, An Endoglycosidase, Indicated For The Treatment Of

  

• OPZELURA® (ruxolitinib) cream 1.5% by Incyte Corporation

  
  

  INCYTE CORPORATION

  Opzelura Is Indicated For The Topical Short-Term And Non-Continuous Chronic Treatment Of Mild To Moderate Atopic Dermatitis In Non-Immunocompromised Adult And Pediatric Patients 12 Years Of Age And Older Whose Disease Is Not Adequately Controlled With Topical Prescription Therapies Or When Those Therapies Are Not Advisable. Opzelura Is Indicated For The Topical Treatment Of Nonsegmental Vitiligo In Adult And Pediatric Patients 12 Years Of Age And Older. Limitations Of Use: Use Of Opzelu

  

• SUNOSI® (solriamfetol)

  
  

  AXSOME THERAPEU

  Sunosi Is Indicated To Improve Wakefulness In Adults With Excessive Daytime Sleepiness (Eds) Associated With Narcolepsy Or Obstructive Sleep Apnea (Osa).

  

• KEYTRUDA® (pembrolizumab) is sponsored by Merck.

  
  

  MERCK SHARP & D

  Adjuvant Therapy For Melanoma Keytruda Is Indicated For The Adjuvant Treatment Of Adult And Pediatric (12 Years And Older) Patients With Stage Iib, Iic, Or Iii Melanoma Following Complete Resection. Adjuvant Treatment For Renal Cell Carcinoma (Rcc) Keytruda Is Indicated For The Adjuvant Treatment Of Patients With Renal Cell Carcinoma (Rcc) At Intermediate-High Or High Risk Of Recurrence Following Nephrectomy, Or Following Nephrectomy And Resection Of Metastatic Lesions.

  

• VOWST (fecal microbiota spores, live-brpk) capsules, sponsored by Nestle Health Sciences and Seres Therapeutics

  
  

  NESTLE-SERES

  Vowst Is A Prescription Medicine Used To Prevent Clostridioides Difficile (C. Diff) Infection From Coming Back In People 18 Years Of Age Or Older After Antibiotic Treatment For C. Diff Infection Has Been Completed.

  

• SYFOVRE® (pegcetacoplan injection), sponsored by Apellis Pharmaceuticals, Inc.

  
  

  APELLIS PHARMAC

  Syfovre® (Pegcetacoplan Injection) Is Indicated For The Treatment Of Geographic Atrophy (Ga) Secondary To Age-Related Macular Degeneration (Amd).

  

• Jakafi® (ruxolitinib) - Incyte Corporation

  
  

  Incyte Corporation

  Jakafi Is Indicated For Treatment Of Intermediate Or High-Risk Myelofibrosis, Including Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis And Post-Essential Thrombocythemia Myelofibrosis In Adults, And, Polycythemia Vera In Adults Who Have Had An Inadequate Response To Or Are Intolerant Of Hydroxyurea, And Steroid-Refractory Acute Graft-Versus-Host Disease In Adult And Pediatric Patients 12 Years And Older.